Trial Evaluated Heated Chemotherapy for Ovarian Cancer
South Carolina patient participated in a study testing if heated chemotherapy improves outcomes for Stage 4 cancer.
Updated on Oct. 2, 2026 in Cancer
Debra Jean Chandler, who received a Stage 4 ovarian cancer diagnosis in October 2024, participated in the Heated Ovarian Treatment Trial. The research evaluates whether adding heated intraperitoneal chemotherapy to standard surgery can better delay or prevent cancer recurrence.
Why it matters
Researchers are investigating whether this specialized approach to chemotherapy can improve survival rates for advanced ovarian cancer. By comparing outcomes between surgical groups, the study aims to determine the efficacy of heat-based treatment in preventing disease return.
The Heated Ovarian Treatment Trial monitors patients like Debra Jean Chandler to compare survival and recurrence after cytoreductive surgery with or without heated intraperitoneal chemotherapy. While preliminary results show no evidence of disease in some participants, the full trial outcomes are pending.
The players
Debra Jean Chandler
A South Carolina resident who participated in the Heated Ovarian Treatment Trial following a Stage 4 ovarian cancer diagnosis.
Brian Orr
The surgeon who performed the cytoreductive procedure as part of the patient's care plan.
MUSC Hollings Cancer Center
An NCI-designated cancer center in South Carolina that coordinates oncology research and patient care.
McLeod Regional Medical Center
A medical facility in Florence, South Carolina, where the patient received chemotherapy treatment.
The details
The treatment involves cytoreductive surgery to remove visible tumor masses, followed by the application of chemotherapy heated to a specific temperature directly into the abdominal cavity. This method is intended to target residual cancer cells more effectively than systemic chemotherapy alone. Following the procedure, trial participants also receive niraparib as maintenance therapy for up to three years to further suppress tumor growth.
Timeline
October 2024: Debra Jean Chandler received a Stage 4 ovarian cancer diagnosis.
February 2025: Brian Orr performed cytoreductive surgery on the patient.
Health Landscape
The Heated Ovarian Treatment Trial represents an evolution in surgical oncology that seeks to improve outcomes beyond standard chemotherapy. It builds on the current clinical strategy of combining cytoreductive surgery with targeted, localized therapies for advanced-stage disease.
Patients with advanced ovarian cancer should discuss all available clinical trial options with their oncologist to see if localized therapies are appropriate. It is important to review the potential benefits and side effects of maintenance therapies like niraparib with a physician.
The takeaway
Advanced ovarian cancer care is increasingly focused on combining surgical intervention with localized therapies to improve long-term outcomes. If you or a loved one are facing a similar diagnosis, ask your care team about clinical trials currently open for enrollment in your region.
Further reading
Learn more about the latest research and standard treatment pathways in Cancer.
Source note: This article includes information reported by Post and Courier.
